Track topics on Twitter Track topics that are important to you
Fintan Walton talks to John Patton, CSO and Co-founder of Nektar Therapeutics about the challenges he faced in setting up the firm and the company’s success to date. John describes how his research at Genentech on inhaled proteins prompted him to set up Nektar (then Inhale Therapeutic Systems), and discusses the resistance he faced from traditional players in the diabetes market when seeking partners.
Since its deals with GlaxoSmithKline and Pfizer in 2004 - both for Nektar’s PEGylation technology - and its subsequent acquisition of Aerogen, the 1.3billion-dollar company has gone from strength to strength. John outlines the business strategy for Nektar going forward and also discusses the company’s product pipeline.
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...